Effect of Polymer Coating (Poly 2-Methoxyethylacrylate) of the Oxygenator on Hemostatic Markers During Cardiopulmonary Bypass in Children

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 21, Issue 1, 2007, Pages 28-34

  Eisses, Michael J ^a   Geiduschek, Jeremy M ^a   Jonmarker, Christer ^a   Cohen, Gordon A ^a   Chandler, Wayne L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

cardiopulmonary bypass; congenital heart surgery; fibrinolysis; hemostasis

Indexed keywords

D DIMER; HEPARIN; POLY 2 METHOXYETHYLACRYLATE; POLYMER; THROMBIN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD CLOTTING; BLOOD SAMPLING; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIBRINOLYSIS; HEART ATRIUM SEPTUM DEFECT; HEART VENTRICLE SEPTUM DEFECT; HEMOSTASIS; HUMAN; INFANT; MALE; MATERIAL COATING; OXYGENATOR; POSTOPERATIVE PERIOD; PRESCHOOL CHILD; PRIORITY JOURNAL; THROMBOCYTE COUNT; TUBE;

BIOLOGICAL MARKERS; BLOOD COAGULATION; CARDIOPULMONARY BYPASS; CHILD, PRESCHOOL; COATED MATERIALS, BIOCOMPATIBLE; FEMALE; FIBRINOLYSIS; HEART DEFECTS, CONGENITAL; HEMOSTASIS; HUMANS; INFANT; MALE; OXYGENATORS; POLYMERS; TIME FACTORS;

EID: 33846652529     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2006.03.023     Document Type: Article

References (22)

1. Despotis G.J., Avidan M.S., and Hogue Jr. C.W. Mechanisms and attenuation of hemostatic activation during extracorporeal circulation. Ann Thorac Surg 72 (2001) S1821-S1831
2. Boisclair M.D., Lane D.A., Philippou H., et al. Mechanisms of thrombin generation during surgery and cardiopulmonary bypass. Blood 82 (1993) 3350-3357
3. Aldea G.S., Lilly K., Gaudiani J.M., et al. Heparin-bonded circuits improve clinical outcomes in emergency coronary artery bypass grafting. J Card Surg 12 (1997) 389-397
4. Dietrich W., Schopf K., Spannagl M., et al. Influence of high- and low-dose aprotinin on activation of hemostasis in open heart operations. Ann Thorac Surg 65 (1998) 70-77 discussion 7-8
5. Ray M.J., and Marsh N.A. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin. Thromb Haemost 78 (1997) 1021-1026
6. Aldea G.S., Soltow L.O., Chandler W.L., et al. Limitation of thrombin generation, platelet activation, and inflammation by elimination of cardiotomy suction in patients undergoing coronary artery bypass grafting treated with heparin-bonded circuits. J Thorac Cardiovasc Surg 123 (2002) 742-755
7. De Somer F., Van Belleghem Y., Caes F., et al. Tissue factor as the main activator of the coagulation system during cardiopulmonary bypass. J Thorac Cardiovasc Surg 123 (2002) 951-958
8. Spiess B., Vocelka C., Cochran R., et al. Heparin-coated bypass circuits (Carmeda) suppress the release of tissue plasminogen activator during normothermic coronary artery bypass graft surgery. J Cardiothorac Vasc Anesth 12 (1998) 299-304
9. Suhara H., Sawa Y., Nishimura M., et al. Efficacy of a new coating material, PMEA, for cardiopulmonary bypass circuits in a porcine model. Ann Thorac Surg 71 (2001) 1603-1608
10. Tanaka M., Motomura T., Kawada M., et al. Blood-compatible aspects of poly(2-methoxyethylacrylate) (PMEA)-Relationship between protein adsorption and platelet adhesion on PMEA surface. Biomaterials 21 (2000) 1471-1481
11. Saito N., Motoyama S., and Sawamoto J. Effects of new polymer-coated extracorporeal circuits on biocompatibility during cardiopulmonary bypass. Artif Organs 24 (2000) 547-554
12. Ninomiya M., Miyaji K., and Takamoto S. Influence of PMEA-coated bypass circuits on perioperative inflammatory response. Ann Thorac Surg 75 (2003) 913-917 discussion 7-8
13. Gunaydin S., Farsak B., Kocakulak M., et al. Clinical performance and biocompatibility of poly(2-methoxyethylacrylate)-coated extracorporeal circuits. Ann Thorac Surg 74 (2002) 819-824
14. Chandler W.L., Jascur M.L., and Henderson P.J. Measurement of different forms of tPA in plasma. Clin Chem 46 (2000) 38-46
15. Eisses M.J., Seidel K., Aldea G.S., et al. Reducing hemostatic activation during cardiopulmonary bypass: A combined approach. Anesth Analg 98 (2004) 1208-1216
16. Chan A.K., Leaker M., Burrows F.A., et al. Coagulation and fibrinolytic profile of paediatric patients undergoing cardiopulmonary bypass. Thromb Haemost 77 (1997) 270-277
17. Despotis G.J., Joist J.H., Hogue Jr. C.W., et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 76 (1996) 902-908
18. Codispoti M., Ludlam C.A., Simpson D., et al. Individualized heparin and protamine management in infants and children undergoing cardiac operations. Ann Thorac Surg 71 (2001) 922-927 discussion 7-8
19. Gorman R., Ziats N., Rao A.K., et al. Cardiopulmonary bypass, myocardial management, and support techniques: Surface-bound heparin fails to reduce thrombin formation during clinical cardiopulmonary bypass. J Thorac Cardiovasc Surg 111 (1996) 1-12
20. Nakajima T., Osawa S., Ogawa M., et al. Clinical study of platelet function and coagulation/fibrinolysis with Duraflo II heparin-coated cardiopulmonary bypass equipment. ASAIO J 42 (1996) 301-305
21. Philippou H., Adami A., Davidson S.J., et al. Tissue factor is rapidly elevated in plasma collected from the pericardial cavity during cardiopulmonary bypass. Thromb Haemost 84 (2000) 124-128
22. Lacour-Gayet F., Clarke D., Jacobs J., et al. The Aristotle score for congenital heart surgery. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 7 (2004) 185-191